Adaptive Pharmacogenomics, LLC

Clinical development for personalized medicine

Tuesday, February 7, 2012 | 4:39 PM

Archive

Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era.

Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era.

Clin Pharmacol Ther. 2010 Dec;88(6):749-51

Authors: Evans BJ

The US Food and Drug Administration (FDA) Amendments Act of 2007, when fully implemented, will offer new sources of evidence and new regulatory mechanisms during the postmarket phase of drug life.

Dec 17, 2010 03:23 AM

Opioid pharmacogenomics using a twin study paradigm: methods and procedures for determining familial aggregation and heritability.

Opioid pharmacogenomics using a twin study paradigm: methods and procedures for determining familial aggregation and heritability.

Twin Res Hum Genet. 2010 Oct;13(5):412-25

Authors: Angst MS, Phillips NG, Drover DR, Tingle M, Galinkin JL, Christians U, Swan GE, Lazzeroni LC, Clark JD

Opioids are the cornerstone medication for the treatment of moderate to severe pain.

Dec 17, 2010 03:23 AM

Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles.

Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles.

Clin Pharmacol Ther. 2010 Dec;88(6):862-6

Authors: Pirmohamed M

The journey from the discovery of a biomarker to its implementation in clinical practice is long and complex.

Dec 17, 2010 03:23 AM

Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.

Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.

J Natl Cancer Inst.

Dec 17, 2010 03:23 AM

Maternal-fetal and neonatal pharmacogenomics: a review of current literature.

Maternal-fetal and neonatal pharmacogenomics: a review of current literature.

J Perinatol.

Dec 17, 2010 03:23 AM

The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.

The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.

Eur J Clin Pharmacol. 2010 Nov;66(11):1109-17

Authors: Jovanović N, Božina N, Lovrić M, Medved V, Jakovljević M, Peleš AM

To evaluate the role of cytochrome 450 2D6 (CYP2D6) and ABCB1 variants on plasma risperidone concentrations and treatment response in 83 drug-naive patients experiencing a first episode of psychosis.

Dec 17, 2010 03:23 AM

Demonstrating utility of pharmacogenetics in pediatric populations: methodological considerations.

Demonstrating utility of pharmacogenetics in pediatric populations: methodological considerations.

Clin Pharmacol Ther. 2010 Dec;88(6):757-9

Authors: Carleton B

Interpretable and meaningful pharmacogenetic data are dependent on accurate characterization of phenotypes. High-quality reports are critical, and important clinical data must not be omitted.

Dec 17, 2010 03:23 AM

Implications of pharmacogenomics for anesthesia providers.

Implications of pharmacogenomics for anesthesia providers.

AANA J. 2010 Oct;78(5):393-9

Authors: Ama T, Bounmythavong S, Blaze J, Weismann M, Marienau MS, Nicholson WT

The practice of anesthesia has long been considered an art and a science, with interpatient variability in drug response being the rule, rather than the exception.

Dec 17, 2010 03:23 AM

Developing pharmacogenetic evidence throughout clinical development.

Developing pharmacogenetic evidence throughout clinical development.

Clin Pharmacol Ther. 2010 Dec;88(6):867-70

Authors: Burns DK

Genetics as a discipline is fundamental for the pharmaceutical industry; it contributes to all therapeutic areas and has an impact throughout the research and development continuum, right up to and including clinical practice.

Dec 17, 2010 03:23 AM

Key information about breast cancer risk and development is found in 'junk' DNA

A new genetic biomarker that indicates an increased risk for developing breast cancer can be found in an individual's "junk" (non-coding) DNA, according to a new study.
Dec 16, 2010 08:00 PM
© 2008 — 2012 Adaptive Pharmacogenomics, LLC